An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Overview of attention for article published in Molecular Cancer Therapeutics, February 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet
patent: 2 patents

wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 29 Dimensions

Readers on

mendeley: 31 Mendeley

Summary News Patents Wikipedia Dimensions citations

So far, Altmetric has seen 1 news story.

Novel Tubulin-Targeting Therapies Make Headway

OncLive, 30 Nov 2020

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.